Icon Wealth Advisors LLC Sells 1,686 Shares of Novo Nordisk A/S (NYSE:NVO)

Icon Wealth Advisors LLC decreased its stake in Novo Nordisk A/S (NYSE:NVO) by 4.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 38,680 shares of the company’s stock after selling 1,686 shares during the period. Icon Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $4,606,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in NVO. Advisor OS LLC raised its holdings in Novo Nordisk A/S by 0.6% during the 2nd quarter. Advisor OS LLC now owns 13,972 shares of the company’s stock valued at $1,994,000 after buying an additional 82 shares during the last quarter. Cascade Financial Partners LLC grew its holdings in shares of Novo Nordisk A/S by 2.3% during the second quarter. Cascade Financial Partners LLC now owns 3,801 shares of the company’s stock valued at $543,000 after buying an additional 84 shares during the last quarter. Novare Capital Management LLC raised its stake in shares of Novo Nordisk A/S by 3.2% in the third quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock worth $325,000 after purchasing an additional 85 shares during the last quarter. AA Financial Advisors LLC lifted its stake in Novo Nordisk A/S by 3.2% during the 2nd quarter. AA Financial Advisors LLC now owns 2,805 shares of the company’s stock valued at $400,000 after acquiring an additional 86 shares during the period. Finally, Steel Grove Capital Advisors LLC lifted its position in Novo Nordisk A/S by 2.3% during the second quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock valued at $541,000 after purchasing an additional 86 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $106.13 on Friday. The business has a 50 day simple moving average of $113.22 and a 200-day simple moving average of $128.18. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15. The stock has a market capitalization of $476.26 billion, a PE ratio of 34.35, a price-to-earnings-growth ratio of 1.37 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Analysts Set New Price Targets

NVO has been the subject of a number of research reports. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. BMO Capital Markets cut their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.